Startup Moat Biotechnology announced the initiation of a funding round led by Cortado Ventures that aims to raise up to $20 million for continued development of the company's intranasal vaccine against COVID-19. According to the announcement, Tetherex Pharmaceuticals has spun out MoatBio in order to develop single-cycle adenovirus vaccines based on SC-AdVax … [Read more...] about Startup Moat Biotechnology announces funding round, positive interim Phase 1 results for its intranasal COVID-19 vaccine
Business
Akorn settles False Claims Act case involving continued sales of azelastine nasal spray as prescription-only after OTC conversion
The US Department of Justice has announced that Akorn will pay $7.9 million to settle a case related to submission of false claims to Medicare Part D after the company continued to sell three products, including azelastine nasal spray, as prescription drugs after conversion to over-the-counter. The allegations were initially made in a suit brought by a whistleblower … [Read more...] about Akorn settles False Claims Act case involving continued sales of azelastine nasal spray as prescription-only after OTC conversion
RIGImmune to develop intranasal stem-loop RNA therapeutics
Yale University spinout RIGImmune, which has been developing stemloop RNA (SLR) therapeutics, announced that it has acquired biotech Subintro, which has been working on antivirals for RNA virus-caused respiratory infections. The company will now develop intranasal therapeutics "that both activate the natural immune activation and demonstrate antiviral activity," … [Read more...] about RIGImmune to develop intranasal stem-loop RNA therapeutics
ALS Association to fund preclinical study of intranasal foralumab
According to Tiziana Life Sciences, The ALS Association will award a Lawrence & Isabel Barnett Drug Development Program Grant to the Ann Romney Center for Neurologic Diseases at the Brigham and Women’s Hospital (BWH) for a preclinical study of Tiziana's intranasal foralumab anti-CD3 monoclonal antibody. The company said that researchers at BWH will evaluate the … [Read more...] about ALS Association to fund preclinical study of intranasal foralumab
Respira Technologies changes its name to Qnovia
Nebulizer developer Respira Technologies, which recently announced the appointment of Brian Quigley as CEO, has changed its name to "Qnovia," the company said. No reason for the name change was announced, but the previous name was similar to that of Respira Therapeutics, which is developing a vardenafil DPI for the treatment of pulmonary arterial hypertension … [Read more...] about Respira Technologies changes its name to Qnovia
Iliad Biotechnology raises $42.8 million for Phase 2b study of BPZE1 intranasal pertussis vaccine
Illiad Biotechnologies has closed a $42.8 million financing round, the company said, with the funds intended to support a Phase 2b challenge study of the company's BPZE1 intranasal pertussis vaccine as well as other development and manufacturing activities. The company said that the new funding brings the total for development of BPZE1 to more than $100 … [Read more...] about Iliad Biotechnology raises $42.8 million for Phase 2b study of BPZE1 intranasal pertussis vaccine
Court rules that Liquidia’s Yutrepia treprostinil DPI would infringe United Therapeutics patents covering Tyvaso
The United States District Court for the District of Delaware has ruled that Liquidia's Yutrepia treprostinil DPI would infringe claims contained in US patents 9,593,066 and 10,716,793, which cover United Therapeutics' Tyvaso inhaled treprostinil; however, the judge found that the claims in the '066 patent that would be infringed are invalid and the sole valid claim … [Read more...] about Court rules that Liquidia’s Yutrepia treprostinil DPI would infringe United Therapeutics patents covering Tyvaso
Orexo gets European patent covering OX640 intranasal dry powder adrenaline
The European Patent Office (EPO) has granted Orexo a patent (EP 3962455B1) covering the company's OX640 intranasal dry powder adrenaline, which is in Phase 1 development for the emergency treatment of anaphylaxis. According to the company, the European patent will protect OX640 until May 2041. OX640 intranasal adrenaline is based on the same technology as the … [Read more...] about Orexo gets European patent covering OX640 intranasal dry powder adrenaline
Hikma launches Ryaltris nasal spray in the US
Hikma Pharmaceuticals has launched Ryaltris olopatadine / mometasone nasal spray in the US, the company said. Hikma acquired US rights to Ryaltris in February 2020, and the FDA approved Glenmark's NDA for the nasal spray for the treatment of seasonal allergic rhinitis in January 2022. The company's US catalog includes several other nasal sprays, including … [Read more...] about Hikma launches Ryaltris nasal spray in the US
Wockhardt subsidiary Morton Grove Pharmaceuticals ordered to stop manufacturing
A US District Court has ordered Wockhardt subsidiary Morton Grove Pharmaceuticals "to stop manufacturing and distributing drugs alleged to be adulterated." The Morton Grove facility manufactured fluticasone propionate nasal sprays in addition to other products. The company has signed a consent decree agreeing to cease production, to destroy already manufactured drugs, … [Read more...] about Wockhardt subsidiary Morton Grove Pharmaceuticals ordered to stop manufacturing